Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Intrasense S.A. specializes in developing and marketing medical imaging software. Its primary function is to enhance the interpretation and analysis of complex medical images through its flagship product, Myrian. Myrian integrates medical imaging data seamlessly for healthcare professionals, enabling precise diagnostics and treatment decisions. The technology is particularly impactful in radiology, oncology, and surgery, where it aids in the visualization and understanding of medical conditions. Intrasense S.A. plays a significant role in modern medical diagnostics by improving the accuracy and efficiency of image-based insights, ultimately advancing patient care. With a growing need for advanced medical imaging solutions, the company continues to influence the healthcare industry by providing innovative tools that streamline medical evaluation processes.
The business is unprofitable at the operating level (-202.03% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 28.4% YoY with margins expanding 20.2pp.
ROIC dropped from -49.40% to -55.90%, capital efficiency is deteriorating.
Profitability & Returns
Revenue (TTM)
€3M
▲ +28.4% YoY
Net Income (TTM)
-€11M
▼ -110.0% YoY
Op. Margin
-202.03%
▲ +20.2pp YoY
ROIC
-55.90%
▼ -6.5pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow
N/A
Net Debt
€9M
Cash & Equiv.
€797K
3Y CAGR: -7.6%
Continue Research